Possible mechanisms of drug-induced aspirin and clopidogrel resistance

Journal of Thrombosis and Thrombolysis

Volumn 22, Issue 2, 2006, Pages 139-150

  Schroeder, Walter S ^a   Ghobrial, Linda ^c   Gandhi, Pritesh J ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

^c NONE

Author keywords

Aspirin; Clopidogrel; Drug interaction; HMG CoA reductase inhibitors; NSAID; Statin

Indexed keywords

2,3 DIHYDROXYBENZOIC ACID; ACETYLSALICYLIC ACID; ATORVASTATIN; CERIVASTATIN; CLOPIDOGREL; CYCLOOXYGENASE 1; CYTOCHROME P450 3A4; DICLOFENAC; GENTISIC ACID; HYDROXYBENZOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LUMIRACOXIB; MEVINOLIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PRAVASTATIN; ROFECOXIB; SALICYL GLUCURONIDE; SALICYLIC ACID; SALICYLURIC ACID; SIMVASTATIN; THIOL DERIVATIVE; THROMBOXANE B2;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; HEALTH CARE; HEART MUSCLE ISCHEMIA; HUMAN; IN VITRO STUDY; LONG TERM CARE; MEDICAL LITERATURE; NONHUMAN; PATIENT COUNSELING; PHYSICIAN; POST HOC ANALYSIS; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 33749171078     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-8670-y     Document Type: Review

References (55)

1. Thom T, et al (2006) Heart disease and stroke statistics-2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113(6):e85-151
2. Ryan TJ, et al (1999) 1999 update: ACC/AHA Guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 100(9):1016-1030
3. Final report on the aspirin component of the ongoing Physicians' Health Study (1989). Steering committee of the physicians' health study research group. N Engl J Med 321(3):129-135
4. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998, 351(9098):233-241
5. Hansson L, et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial HOT Study Group. Lancet 351(9118):1755-1762
6. de Gaetano G (2001) Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 357(9250):89-95
7. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348(9038):1329-1339
8. Yusuf S, et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494-502
9. Serebruany VL, et al (2003) Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: The Plavix Use for Treatment of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 146(4):713-720
10. Mehta SR, et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358(9281):527-533
11. Sabatine MS, et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352(12):1179-1189
12. Braunwald E, et al (2002) ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 106(14):1893-1900
13. Smith SC, Jr, et al (2006) ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary intervention-summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113(1):156-175
14. Bhatt DL, et al. (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med.
15. Gum PA, et al (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41(6):961-965
16. Gum PA, et al (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88(3):230-235
17. Grundmann K, et al (2003) Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250(1):63-66
18. Grotemeyer KH, Scharafinski HW, Husstedt IW (1993) Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 71(5):397-403
19. Chen WH, et al (2004) Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43(6):1122-1126
20. Matetzky S, et al (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109(25):3171-3175
21. Wiviott SD, Antman EM (2004) Clopidogrel resistance: A new chapter in a fast-moving story. Circulation 109(25):3064-3067
22. Jack DB (1997) One hundred years of aspirin. Lancet 350(9075): 437-439
23. Benedek IH, et al (1995) Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 35(12):1181-1186
24. Patrono C, et al (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353(22):2373-2383
25. Juul-Moller S, et al (1992) Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 340(8833):1421-1425
26. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 1990, 336(8719):827-830
27. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet 1991, 338(8779):1345-1349
28. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Bmj 1994, 308(6921):81-106
29. Helgason CM, et al (1994) Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25(12):2331-2336
30. Pappas JM, Westengard JC, Bull BS (1994) Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 118(8):801-804
31. Catella-Lawson, F et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809-1817
32. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340(2):115-126
33. MacDonald TM, Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361(9357):573-574
34. Kurth T, et al (2003) Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108(10):1191-1195
35. Jermany J, et al (2005) Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects. J Clin Pharmacol 45(10):1172-1178
36. Capone ML, et al (2005) Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45(8):1295-1301
37. Pereillo JM, et al (2002) Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30(11):1288-1295
38. Reist M, et al (2000) Very slow chiral inversion of clopidogrel in rats: A pharmacokinetic and mechanistic investigation. Drug Metab Dispos 28(12):1405-1410
39. Gurbel PA, et al (2003) Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction of New Thrombus occurrence (PRONTO) trial. Am Heart J 145(2):239-247
40. Gurbel PA, et al (2005) The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45(9):1392-1396
41. Clarke TA, Waskell LA (2003) The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 31(1):53-59
42. Ding Z, et al (2003) Inactivation of the human P2Y 12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101(10):3908-3914
43. Daniel JL, et al (1998) Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 273(4):2024-2029
44. Geiger J, et al (1999) Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 19(8):2007-2011
45. Horstrup K, et al (1994) Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem 225(1):21-27
46. Savi P, et al (1994) Binding of [3H]-2-methylthio ADP to rat platelets-effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 269(2):772-777
47. Shattil SJ, Kashiwagi H, Pampori N (1998) Integrin signaling: The platelet paradigm. Blood 91(8):2645-2657
48. Storey RF, et al (2002) Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y 12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 88(3):488-494
49. Cannon CP, et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350(15):1495-1504
50. Lau WC, et al (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 107(1):32-37
51. Neubauer H, et al (2003) Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - A flow cytometry study. Eur Heart J 24(19):1744-1749
52. Serebruany VL, et al (2004) Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study. Arch Intern Med 164(18):2051-2057
53. Saw J, et al (2003) Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108(8):921-924
54. Mitsios JV, et al (2005) The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes. Platelets 16(5):287-292
55. Mukherjee D, et al (2005) Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 91(1):23-26